Borosil Scientific reported a consolidated net profit of ₹4.36 crore for Q1 FY2027, a significant turnaround from a loss in the previous year. The Glassware segment also recovered, moving into profitability. The company also approved changes to its ESOP schemes.
Borosil Scientific Swings to Profit in Q1 FY27
Consolidated Net Profit: ₹4.36 crore (₹435.51 lakh) Standalone Revenue: ₹99.90 crore (₹9,989.68 lakh) ## What just happened Borosil Scientific Ltd. reported a consolidated net profit of ₹4.36 crore for the first quarter of FY2027 (ending June 30, 2026). This marks a significant improvement from the ₹4.21 crore loss recorded in the same quarter last year (Q1 FY2026). The company's consolidated revenue also saw growth, rising to ₹106.75 crore in Q1 FY2027 from ₹95.98 crore in Q1 FY2026. Standalone revenue for the quarter stood at ₹99.90 crore, up from ₹89.01 crore in the prior year's quarter. A key highlight was the turnaround in the Glassware segment, which reported a profit of ₹0.19 crore after incurring a loss of ₹2.40 crore in the year-ago period. ## Why this matters The shift to consolidated profitability and the recovery in the crucial Glassware segment indicate a strengthening of Borosil Scientific's operational performance. This turnaround is a positive sign for investors, suggesting that the company's strategies are yielding results. ## The backstory In Q1 FY2026, Borosil Scientific faced a consolidated loss of ₹4.21 crore and its Glassware segment was also in the red. The current quarter's results demonstrate a significant recovery from that challenging period. ## What changes now The Board of Directors has approved modifications to the company's ESOP schemes, SP-ESOP 2023 and BSL ESOS. These changes include adopting the trust route for share allocation and increasing the discount limit for new option grants from 10% to 20%. These amendments are designed to provide greater flexibility in employee incentives. ## Risks to watch Investors will need to monitor if the current levels of profitability and margin improvement can be sustained in the upcoming quarters, given the competitive landscape. ## Peer comparison (No peer comparison data available in the filing.) ## Context metrics (time-bound) * **Consolidated Revenue:** ₹106.75 crore (Q1 FY2027) vs ₹95.98 crore (Q1 FY2026) * **Consolidated Profit/(Loss):** ₹4.36 crore (Q1 FY2027) vs (₹4.21 crore) (Q1 FY2026) * **Glassware Segment Profit/(Loss):** ₹0.19 crore (Q1 FY2027) vs (₹2.40 crore) (Q1 FY2026) ## What to track next Investors should keep an eye on future revenue growth trends, the sustainability of segment-wise margins, and the overall market conditions impacting the laboratory and scientific products sector. Reader Takeaway: Improved profitability and segment recovery signal strength, but sustained momentum is key.
